Inhibition and Modulation Factor IX Activity with a Novel Aptamer System during PCI - Rationale for the REGULATE Trial - A. Michael Lincoff, MD

↳ This is a section part of Moment: CRT 2015 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Inhibition and  Modulation Factor IX  Activity with a Novel Aptamer System during PCI - Rationale for the REGULATE Trial presented by A. Michael Lincoff, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management
Loading Simple Education